Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Innovative Medical |
---|---|
Information provided by: | Innovative Medical |
ClinicalTrials.gov Identifier: | NCT00348400 |
Evaluate the relative efficacy and tolerability of Alphagan P compared to Trusopt as adjunctive therapy
Condition | Intervention | Phase |
---|---|---|
Glaucoma |
Drug: Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost |
Phase IV |
Study Type: | Interventional |
Study Design: | Randomized, Single Blind, Active Control, Parallel Assignment |
Official Title: | Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
· Male or female > 18 years of age
Exclusion Criteria:
· Known contraindication or allergy to brimonidine or any of its components
Study ID Numbers: | 5099 |
Study First Received: | June 30, 2006 |
Last Updated: | May 30, 2007 |
ClinicalTrials.gov Identifier: | NCT00348400 |
Health Authority: | United States: Institutional Review Board |
Glaucoma Eye Diseases Latanoprost Dorzolamide |
Brimonidine Hypertension Ocular Hypertension |
Carbonic Anhydrase Inhibitors Neurotransmitter Agents Adrenergic alpha-Agonists Molecular Mechanisms of Pharmacological Action Adrenergic Agents Therapeutic Uses |
Physiological Effects of Drugs Enzyme Inhibitors Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions Adrenergic Agonists |